Webinar: Accelerating Antibody Discovery: Integrating Microfluidics, HT Expression, and Early Developability Platform by InsideScientific

Accelerating Antibody Discovery: Integrating Microfluidics, HT Expression, and Early Developability Platform

About

In this webinar, Dr. Lei Shi introduces Biointron's antibody discovery platform and applications.

Increasingly, antibody drug development requires quick and holistic assessment from the discovery stage with a powerful platform, which demands experienced scientists make smart and strategic choices. We will discuss how Biointron's unique single B cell sorting-based antibody screening can help identify a population of diverse and functional hits with a shortened timeline. Integrated with our high-throughput expression, validation and developability assay platforms, the path from hits to candidate can be more faster and more efficient with data beyond binding alone.

Presenter

Lei Shi, PhD

SVP Biointron

Lei Shi, PhD is Senior Vice President of Biointron. He has more than 20 years of experience in antibody discovery. Previously, Lei worked for a number of pharmaceutical and biotech companies such as Johnson & Johnson with increasing responsibilities. He completed his postdoc research at MGH and Harvard Medical School and has an Executive Master's degree from the University of Pennsylvania.

First Name*

Last Name*

Email Address*

Country / Region*

Job Title*

Organization / Company*

Organization Type*

What is your primary area of focus?*

Antibody discovery

Protein engineering

Drug development

Other (please specify)

Are you currently outsourcing or planning to outsource antibody discovery or related services?*

Yes, currently outsourcing

Planning to outsource in the next 6 months

Considering, but no timeline yet

Not planning to outsource

Have you heard of Biointron before?*

Yes, very familiar

Yes, somewhat familiar

No, not familiar

utm_bmcr_source